Skip to main content
AMGN
NASDAQ Life Sciences

Amgen Q3 Revenue Up 8% to $10.4B, Full-Year Guidance Raised to $38.9-39.7B

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$463
Mkt Cap
$249.372B
52W Low
$292.12
52W High
$475.645
52W Position info
58% above low
Off High info
2.7% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

AMGN sits 58% above its 52-week low of $292.12.

Summary

Amgen posted Q3 2026 revenue of $10.4B, up 8%, and non-GAAP EPS of $6.45, up 14%, then raised full-year revenue guidance to $38.9-39.7B. Offsetting that: biosimilar erosion in Prolia and XGEVA and the pending TAVNEOS withdrawal.


Key Events · Earnings and Guidance · AMGN

  • Q3 Revenue $10.4B, Up 8%

    Total revenues rose 8% to $10.4 billion from $9.557 billion, with product sales up 8% to $9.883 billion on volume growth.

  • EPS Growth and Margin Expansion

    GAAP EPS rose 19% to $7.08 from $5.93 and non-GAAP EPS rose 14% to $6.45 from $5.64; GAAP operating margin expanded 9.9 points to 37.5%.

  • Full-Year Guidance Raised

    2026 revenue guidance was lifted to $38.9-39.7 billion from the $38.2-39.4 billion range given in August; non-GAAP EPS is guided to $22.90-23.70 and GAAP EPS to $18.34-19.28.

  • Biosimilar Erosion Deepens

    Prolia sales fell 45% to $632 million and XGEVA fell 47% to $288 million as multiple biosimilars launched globally, partly offsetting growth products Repatha (+37% to $1,085 million) and UPLIZNA (+191% to $451 million).


Analysis · AMGN · Life Sciences

The number that matters for the thesis is the raised guidance: full-year sales are now seen at $38.9-39.7B, up from $38.2-39.4B in August, after the company beat its own revenue outlook, and non-GAAP EPS came in at $6.45, up 14%. Growth products are doing the heavy lifting — Repatha rose 37% to $1,085M, UPLIZNA 191% to $451M and IMDELLTRA 128% to $406M. Against that, biosimilar erosion is steep and accelerating, with Prolia down 45% to $632M and XGEVA down 47% to $288M. TAVNEOS remains under an FDA request to withdraw; a hearing was requested June 1 and supporting materials were submitted July 23. Free cash flow slipped to $3.7B from $4.2B on working capital, and the balance sheet carries $54.0B of debt against $13.2B of cash.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AMGN was trading at $463.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $249.4B. The 52-week trading range was $292.12 to $475.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AMGN - Latest Insights

AMGN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $477.40
Real-time Price: $446.87 info
Change: -$30.54 (-6%) info
Market Cap: $241.714B info
AMGN
Nov 03, 2026, 6:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $464.92
Real-time Price: $446.87 info
Change: -$18.06 (-4%) info
Market Cap: $241.714B info
AMGN
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $460.57
Real-time Price: $446.87 info
Change: -$13.70 (-3%) info
Market Cap: $241.714B info
AMGN
Oct 26, 2026, 9:23 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $448.79
Real-time Price: $446.87 info
Change: -$1.93 (-0.43%) info
Market Cap: $241.714B info
AMGN
Oct 24, 2026, 10:30 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $439.26
Real-time Price: $446.87 info
Change: +$7.61 (+2%) info
Market Cap: $241.714B info